肺癌患者丝裂原活化蛋白激酶1(MAPK1)表达水平及临床意义  

Expression levels and clinical value of mitogen-activated protein kinase1 (MAPK1) in patients with lung cancer

作　　者：陈伟庄[1] 吴宏成[2] 

机构地区：[1]宁波大学,浙江宁波315040 [2]宁波大学医学院附属李惠利医院,浙江宁波315040

出　　处：《临床肺科杂志》2013年第3期395-397,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的检测肺癌患者血浆中丝裂原活化蛋白激酶1(MAPK1/ERK2)表达水平及探讨其与肺癌类型、临床分期、TNM分期的关系。方法用ELISA法分别检测肺癌组(n=78),良性肺部疾病组(n=27),健康对照组(n=14)血浆中MAPK1/ERK2的水平含量。结果肺癌患者血浆中MAPK1/ERK2的含量高于良性肺部疾病组和健康对照组(P<0.05),良性肺部疾病组高于健康对照组(P<0.05)。肺癌患者血浆中MAPK1/ERK2的表达与性别,年龄,吸烟状况,肿瘤病理类型,临床分期,TNM分期无显著性差异。结论 MAPK1/ERK2对肺癌的辅助诊断有一定的临床价值,可作为一项新的肺癌生物标志物应用。Objective To detect the level of MAPK1/ERK2 in the plasma of lung cancer patients and to explore its relationship with types, clinical stage, TNM stage of lung cancer. Methods The levels of MAPK1/ERK2 in plasma were detected by ELISA in 78 patients with lung cancer, 27 patients with benign lung diseases, and 14 healthy people. Results The levels of MAPK1/ERK2 were sig- nificantly higher in patients with lung cancer than in the healthy controls and those with benign lung diseases （ P 〈 0. 05 ） while the levels of MAPK1/ERK2 were significantly higher in patients with benign lung diseases than in the healthy controls （P 〈 O. 05 ）. The levels of MAPK1/ERK2 were not significantly related to sex, age, smoking status, the type of lung cancers, clinical stage, and TNM stage. Con- clusion MAPK1/ERK2 may have a certain clinical value to aid the diagnosis of lung cancer. It can be used as a novel biological marker for lung cancer.

关 键 词：丝裂原活化蛋白激酶1 细胞外信号调节激酶2 丝裂原活化蛋白激酶信号通路 肺癌 生物标志物 

分 类 号：R734.2[医药卫生—肿瘤]